WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with …
Category: Business
Stanton Optical Opens New Store in Boise Area
BOISE, Idaho–(BUSINESS WIRE)–Stanton Optical, a leading full-service optical retailer offering accessible and affordable eye care and eyewear, opened its newest location in Boise on Monday, December 14. Located at 1405 N. Milwaukee Street, the new st…
Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases
LONDON–(BUSINESS WIRE)– #GeneTherapy–Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases.
Kubota Vision Provides Update on Kubota Glasses – Wearable Device for Myopia Control
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (Kubota Vision), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today announced that the company achieved a milestone b…
IVERIC bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
NEW YORK–(BUSINESS WIRE)–IVERIC bio announced that Glenn P. Sblendorio, CEO and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2021.
Horizon Therapeutics plc Announces Short-Term TEPEZZA® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) announced that it expects a short-term disruption in TEPEZZA (teprotumumab-trbw) supply as a result of recent government-mandated COVID-19 vaccine production orders related to Operation W…
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
NEW YORK–(BUSINESS WIRE)– #Eyenovia–Eyenovia has enrolled its first patients in the Phase 3 VISION-1 Study of MicroLine for the improvement in near vision in patients with presbyopia.
Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
My Eyelab and Stanton Optical Unveil New Line of Disney-Themed Frames for Children
PALM SPRINGS, Fla.–(BUSINESS WIRE)–My Eyelab and Stanton Optical, leading retail brands of Now Optics offering accessible and affordable eye care and eyewear, announced today the release of an exclusive line of frames for children in the Disney, Marv…
Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is kicking off a virtual R&D Day event today. During the two-day event, the Company plans to showcase its commercial and R&D…
Avellino Expands Its Board of Directors and Welcomes New Executive Management Members
MENLO PARK, Calif.–(BUSINESS WIRE)– #avagen–Avellino announces three new board members and two new executive management members to the continuously growing precision medicine company.
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the “Company” or “GenSight”), a biopharma company focused on developing and commercializing innovative gene therapies for…
GenSight Biologics annonce la conversion partielle des obligations convertibles et l'exercice de l'intégralité des bons de souscription d'actions par Kreos Capital
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME) (Paris:SIGHT) (la « Société » ou « GenSight »), société biopharmaceutique dédiée au développement et à la commercialisation de thérapi…
Neuromyelitis Optica (Devic's Syndrome) Pipeline Review, H2 2020 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Neuromyelitis Optica (Devic’s Syndrome) – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering. Neuromyelitis Optica – Pipeline Review, H2 2020, provides comprehensive information on…
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)—- $KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors,…
中外製藥的Enspryng成為臺灣核准的首款用於泛視神經脊髓炎(NMOSD)的藥物
東京–(BUSINESS WIRE)–(美國商業資訊)–中外製藥株式會社(Chugai Pharmaceutical Co., Ltd., TOKYO:4519)宣布，中外製藥的獨資子公司Chugai Pharma Taiwan Ltd.的Enspryng®獲得臺灣食品藥物管理署(TFDA)的進口藥物許可，Enspryng®用於治療抗水通道蛋白-4(AQP4)抗體陽性的泛視神經脊髓炎(NMOSD) 12歲以上成人和青少年患者。 中外製藥總裁兼營運長Osamu Okuda博士表示：「我們很高興的…
GenSight Biologics annonce la publication dans Science Translational Medicine des résultats de l’essai pivot de phase III REVERSE et d’une étude sur des primates avec LUMEVOQ®
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le tr…
GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative dis…
My Eyelab Opens New Store in Atlanta Area
CONYERS, Ga.–(BUSINESS WIRE)–My Eyelab, a leading optical retailer offering accessible and affordable eye care and eyewear, opened its newest location in Conyers, GA on Monday, December 7. Located at 1285 GA-138, the new store marks My Eyelab’s 90th …